China Pharma Holdings, Inc. to Report Second Quarter of Fiscal Year 2012 Financial Results on August 15, 2012

HAIKOU CITY, China, Aug. 2, 2012 /PRNewswire-Asia-FirstCall/ -- China Pharma Holdings, Inc. ("China Pharma") (NYSE Amex: CPHI), which develops, manufactures, and markets specialty pharmaceutical products in China, today announced that it plans to release its second quarter of year 2012 financial results before the market opens on Wednesday, August 15, 2012.

The Company will hold a conference call at 8:30 am ET on August 15, 2012 to discuss second quarter of year 2012 results.  Listeners may access the call by dialing 1-866-519-4004 or 65-672-393-81 for international callers, Conference ID # 16312392. A webcast will also be available through CPHI's website at http://www.chinapharmaholdings.com.  A replay of the call will be accessible through August 23, 2012 by dialing 1-866-214-5335 or 61-282-355-000 for international callers, Conference ID # 16312392.

About China Pharma Holdings, Inc.

China Pharma Holdings, Inc. is a specialty pharmaceutical company with rapidly growing profit that develops, manufactures, and markets treatments for a wide range of high incidence and high mortality conditions in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective, high margin business model is driven by market demand and supported by eight scalable GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding distribution network across 30 provinces, municipalities and autonomous regions. The Company is registered in Delaware, USA. Hainan Helpson Medical & Biotechnology Co., Ltd. (Helpson), located in Haikou City, Hainan Province, China, is a wholly owned subsidiary of China Pharma Holdings, Inc. For more information about China Pharma Holdings, Inc., please visit http://www.chinapharmaholdings.com.

Contact:

China Pharma Holdings, Inc.    
Phone: +86-898-6681-1730 (China)              
Email: [email protected]      

SOURCE China Pharma Holdings, Inc.